What We're Reading: Page 179
Industry reads hand-picked by our editors
Aug 13, 2020
-
The Boston Globe
A new approach to ALS drug trials gives patients hope
-
The Wall Street Journal
Beset by Coronavirus, Health Authorities Brace for Flu Season
-
Endpoints News
Novartis' CAR-T partner in China wraps $383M take-private deal engineered by CEO
-
STAT
Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment
Aug 12, 2020
-
The New York Times
How Russia’s Rushed Covid-19 Vaccine Could Backfire
-
The Wall Street Journal
Kodak Insider Makes Well-Timed Stock Gift of $116 Million to Religious Charity He Started
-
Reuters
Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in August
-
Evaluate Vantage
Contingent value is back in vogue
Aug 11, 2020
Aug 10, 2020
-
The New York Times
This Company Boasted to Trump About Its Covid-19 Vaccine. Experts Are Skeptical.
-
The Wall Street Journal
During Covid-19 Pandemic, Biotech IPOs Already Surpass Record
-
STAT
Pharma is showering Congress with cash, even amid coronavirus
-
Boston Business Journal
Biogen's Alzheimer's drug has a name. Here's what it is.
Aug 07, 2020
Aug 06, 2020
-
The Washington Post
FDA commissioner Stephen Hahn: Only a safe, effective vaccine will get our approval
-
The Wall Street Journal
Bausch Health to Spin Off Eye-Care Business
-
San Francisco Business Times
State AGs urge federal government to 'march in' on Gilead's Covid drug remdesivir
-
Endpoints News
Less than 3 months after launch, the AveXis crew's Taysha raises $95M Series B. Is an IPO next?
Previous
